Vertex Pharmaceuticals (VRTX)

As of March 20, 2026, Vertex Pharmaceuticals (NASDAQ: VRTX) has officially transcended its long-held identity as "the cystic fibrosis (CF) company." For over a decade, the Boston-based biotech giant dominated the CF landscape with its groundbreaking CFTR modulators, but today, the narrative has shifted to a broader multi-disease platform. With the successful 2025 launch of [...]

We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

These companies have impressive track records of navigating the biggest challenges in their industry.

Both have plenty to offer investors, but one has a better outlook.

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASD...

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab...

A new product approval may be right around the corner.

The drugmaker is getting its mojo back.

Vertex Pharmaceuticals’s 22.2% return over the past six months has outpaced the S&P 500 by 19.8%, and its stock price has climbed to $480.31 per share. This ...

In a significant milestone for precision medicine, Vertex Pharmaceuticals (NASDAQ:VRTX) emerged as the top performer in the S&P 500 on March 11, 2026, with its shares climbing 8.3%. The rally followed the release of highly encouraging clinical data and operational updates from its renal pipeline, specifically targeting

Check out the companies making headlines yesterday: nLIGHT (NASDAQ:LASR): Laser company nLIGHT (NASDAQ:LASR) rose by 5.5% on Tuesday after the market reacted...

What Happened? Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 8.3% in the afternoon session after the company announced positive resul...

The healthcare sector has entered a period of sharp divergence in early 2026, creating a "bifurcated market" where clinical innovation is rewarding a select few while punishing former industry darlings. As of March 10, 2026, the industry is processing a tale of two trajectories: Vertex Pharmaceuticals (NASDAQ: VRTX) has cemented

Shares of Vertex Pharmaceuticals (Nasdaq: VRTX) climbed more than 8% today, reaching a record high as the biotechnology giant unveiled spectacular interim results from its pivotal Phase 3 RAINIER trial. The data, which focused on povetacicept for the treatment of IgA nephropathy (IgAN), showcased a 52% reduction in proteinuria, a

Data from Stocktwits indicated that retail sentiment on SPY and QQQ was stabilizing.

The company said that patients treated with povetacicept achieved a 52.0% reduction from baseline in urine protein to creatinine ratio at week 36, meeting the study’s key goal.

The company has performed well over the long run.

Both of these players are leaders in their fields.

These two biotechs have a lot in common. Their differences are even more pronounced.

CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.